



TRANSMITTAL FORM

to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

11 + Refs

Application Number

10/553,117

Filing Date

October 13, 2005

First Named Inventor

Aiyar, J. et al.

Art Unit

T/B/A

Examiner Name

T/B/A

Attorney Docket Number

MS0019P

ENCLOSURES (Check all that apply)

☐ Fee Transmittal Form

☐ Fee Attached

☐ Amendment/Reply

☐ After Final

☐ Affidavits/declaration(s)

☐ Extension of Time Request

☐ Express Abandonment Request

☒ Information Disclosure Statement

☐ Certified Copy of Priority Document(s)

☐ Response to Missing Parts/Incomplete Application

☐ Response to Missing Parts under 37 CFR 1.52 or 1.53

☐ Drawing(s)

☐ Licensing-related Papers

☐ Petition

☐ Petition to Convert to a Provisional Application

☐ Power of Attorney, Revocation Change of Correspondence Address

☐ Terminal Disclaimer

☐ Request for Refund

☐ CD, Number of CD(s) _____

☐ After Allowance Communication to Technology Center (TC)

☐ Appeal Communication to Board of Appeals and Interferences

☐ Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)

☐ Proprietary Information

☐ Status Letter

☐ Other Enclosure(s) (please Identify below):

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Name

Vineet Kohli

Registration No. (Attorney/Agent)

37,003

Signature

Date

2/28/2007

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on this date: 2/28/07


Typed or printed name

Terri Schiffman

Signature

Date

2/28/07



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Merck & Co., Inc.

Serial No. 10/553,117

Filed: October 13, 2005

For: SPLICE VARIANTS OF HUMAN VOLTAGE-GATED
CALCIUM CHANNEL $\alpha 2\beta$ -2 SUBUNIT DESIGNATED
 $\alpha 2\beta 2$ -A AND $\alpha 2\beta 2$ -BArt Unit: T/B/AExaminer: T/B/ACommissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.97

Sir:

1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.
4. Pursuant to 37 C.F.R. 1.98 (a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK & CO., INC.

By J. Schiffman Date 2/28/07

**INFORMATION DISCLOSURE STATEMENT**

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:

RELATED APPLICATION		
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE

If this is inconvenient, additional copies will be submitted upon request.

6. In accordance with 37 C.F.R. 1.97, (check one)

- ☐ the attached information is filed within three months of the filing date of the captioned case.
- ☒ the attached information is filed more than three months after the filing date but prior to the mailing of a first Office Action on the merits.
- ☐ the attached information is filed before the mailing of a first Office action after the filing of a request for continued examination under §1.114.
- ☐ the attached information is being filed more than three months after the filing date and after the mailing of a first Office Action on the merits, but before the mailing date of a Final Action, Notice of Allowance, or an action that otherwise closes prosecution in the application. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).
- ☐ each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.
- ☐ each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart application *and this communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of the information disclosure statement.*
- ☐ no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of this Statement.

Respectfully submitted,

By: Vineet Kohli

Attorney _____ For Applicant(s)

Reg. No. 37,003

MERCK & CO., INC.

Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907

(732)594- 3889

Date: February 28, 2007

SUBSTITUTE for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			COMPLETE IF KNOWN		
			Application Number	10/553,117	
			Filing Date	October 13, 2005	
			First Named Inventor	Aiyar et al.	
			Group Art Unit		
			Examiner Name		
Sheet	1	of	8	Attorney Docket Number	MS0019P

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
	A	US2002/0147309		Lipscombe et al.	10/10/2002
	B	5,571,893		Baker et al.	11/05/1996
	C	5,569,825		Lonberg et al.	10/29/1996
	D	5,567,610		Borrebaeck et al.	10/22/1996
	E	5,565,354		Ostberg et al.	10/15/1996
	F	5,559,004		Steinhardt et al.	09/24/1996
	G	5,429,921		Harpold et al.	07/04/1995
	H	5,399,346		Anderson et al.	03/21/1995
	I	5,312,928		Goldin et al.	05/17/1994
	J	5,225,539		Winter et al.	07/06/1993
	K	4,946,778		Ladner et al.	08/07/1990
	L	4,816,567		Cabilly et al.	03/28/1989
	M	4,642,285		Halbert et al.	02/10/1987
	N	4,376,110		David et al.	03/08/1983

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
	O	PCT	WO 01/70949		Graham et al.	09/27/2001
	P	PCT	WO 92/04381		Harris et al.	03/19/1992
	Q	EP	EP 0 125 023		Cabilly et al.	06/05/1991
	R	PCT	WO 87/02671		Robinson et al.	05/07/1987
	S	PCT	WO 86/01533		Neuberger et al.	03/13/1986

Examiner Signature	Date Considered	
--------------------	-----------------	--

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			COMPLETE IF KNOWN		
			Application Number	10/553,117	
			Filing Date	October 13, 2005	
			First Named Inventor	Aiyar et al.	
			Group Art Unit		
			Examiner Name		
Sheet	2	of	8	Attorney Docket Number	MS0019P

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
	1	Tsien et al., "Multiple Types of Neuronal Calcium Channels and Their Selective Modulation", Trends Neurosci., 11(10):431-438, 1988
	2	Catterall, W. A., "Structure and Regulation of Voltage-Gated Ca ²⁺ Channels", Annual Rev. Cell Dev. Biol., 16:521-555, 2000
	3	Llinas et al., "Distribution and Functional Significance of the P-type, Voltage-dependent Ca ²⁺ Channels in the Mammalian Central Nervous System", Trends Neurosci., 15(9):351-355, 1992
	4	Hess, P., "Calcium Channels in Vertebrate Cells", Annual Review Neurosci., 56:337-356, 1990
	5	Bean, B. P., "Classes of Calcium Channels in Vertebrate Cells", Annual. Rev. Physiol., 51:367-384, 1989
	6	Hille, B., Ion Channels of Excitable Membranes, 3rd Ed., Sinauer Associates, Sunderland, Mass., 2001
	7	Marais et al., "Calcium Channel $\alpha 2\delta$ Subunits - Structure and Gabapentin Binding", Molecular Pharmacology, 59(5):1243-1248, 2001
	8	Dunlap et al., "Exocytotic Ca ²⁺ Channels in Mammalian Central Neurons", Trends Neurosci., 18(2):89-98, 1995
	9	Varadi et al., "Molecular Determinants of Ca ²⁺ Channel Function and Drug Action", Trends Pharmacol. Sci., 16:43-49, 1995
	10	Nooney et al., "Identifying Neuronal non-L Ca ²⁺ channels - More than Stamp Collecting?", Trends Pharmacol. Sci., 18:363-371, 1997
	11	Perez-Reyes et al., "Molecular Characterization of a Neuronal Low-voltage-activated T-type Calcium Channel", Nature, 391:896-900, 1998
	12	DeWaard et al., "Structural and Functional Diversity of Voltage-activated Calcium Channels", Ion Channels, ed. T. Narahashi, pages 41-87, Plenum Press, New York, 1996
	13	Catterall, W. A., "Excitation-Contraction Coupling in Vertebrate Skeletal Muscle: A Tale of Two Calcium Channels", Cell, 64:871-874, 1991
	14	Catterall, W. A., "Functional Subunit Structure of Voltage-Gated Calcium Channels", Science, 253:1499-1500, 1991
	15	Hofmann et al., "Voltage-Dependent Calcium Channels: From Structure to Function", Rev. Physiol. Biochem. Pharmacol., 139:33-87, 1999

Examiner Signature	Date Considered
--------------------	-----------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 8/24/2006

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			COMPLETE IF KNOWN		
			Application Number	10/553,117	
			Filing Date	October 13, 2005	
			First Named Inventor	Aiyar et al.	
			Group Art Unit		
			Examiner Name		
Sheet	3	of	8	Attorney Docket Number	MS0019P

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
	16	Lacinova et al., "Low Voltage Activated Calcium Channels: from Genes to Function", Gen. Physiol. Biophys., 19:121-136, 2000
	17	Pérez-Reyes, E. & Schneider, "Molecular Biology of Calcium Channels", Kidney International, 48:1111-1124, 1995
	18	Ellis et al., "Sequence and Expression of mRNAs Encoding the $\alpha 1$ and $\alpha 2$ Subunits of a DHP-Sensitive Calcium Channel", Science, 241:1661-1664, 1988
	19	Schmid et al., "Immunochemical Analysis of Subunit Structures of 1,4-Dihydropyridine Receptors Associated with Voltage-Dependent Ca^{2+} Channels in Skeletal, Cardiac, and Smooth Muscles", Biochemistry, 25:3492-3495, 1986
	20	Angelotti & Hofmann, "Tissue-specific Expression of Splice Variants of the Mouse Voltage-gated Calcium Channel $\alpha 2/\delta$ subunit", Febs Lett., 397: 331-337, 1996
	21	Klugbauer et al., "Molecular Diversity of the Calcium Channel $\alpha 2\delta$ Subunit", J. Neuroscience, 19:(2)684-691, 1999
	22	DeJongh et al., "Subunits of Purified Calcium Channels", J. Biol. Chem., 265(25):14738-14741, 1990
	23	Jay et al., "Structural Characterization of the Dihydropyridine-sensitive Calcium Channel $\alpha 2$ -Subunit and the Associated δ Peptides", J. Biol. Chem., 266(5):3287-3293, 1991
	24	Gao et al., "Functional Properties of a New Voltage-dependent Calcium Channel $\alpha 2\delta$ Auxiliary Subunit Gene (<i>CACNA2D2</i>)", J. Biol. Chem., 275(16):12237-12242, 2000
	25	Gurnett et al., "Dual Function of the Voltage-Dependent Ca^{2+} Channel $\alpha 2\delta$ Subunit in Current Stimulation and Subunit Interaction", Neuron, 16:431-440, 1996
	26	Felix et al., "Dissection of Functional Domains of the Voltage-Dependent Ca^{2+} Channel $\alpha 2\delta$ Subunit", J. Neurosci., 17(18):6884-6891, 1997
	27	Gee et al., "The Novel Anticonvulsant Drug, Gabapentin (Neurontin), Binds to the $\alpha 2\delta$ Subunit of a Calcium Channel", J. Biol. Chem., 271(10):5768-5776, 1996
	28	Bitto et al., " Ca^{2+} -dependent Regulation in Neuronal Gene Expression", Curr. Opin. Neurobiol., 7:419-429, 1997
	29	Toyota et al., "Inactivation of <i>CACNA1G</i> , a T-Type Calcium Channel Gene, by Aberrant Methylation of Its 5' CpG Island in Human Tumors", Cancer Research, 59:4535-4541, 1999

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 8/24/2006

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			COMPLETE IF KNOWN		
			Application Number	10/553,117	
			Filing Date	October 13, 2005	
			First Named Inventor	Aiyar et al.	
			Group Art Unit		
Examiner Name					
Sheet	4	of	8	Attorney Docket Number	MS0019P

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
	30	Charlier et al., "A Pore Mutation in a Novel KQT-like Potassium Channel Gene in an Idiopathic Epilepsy Family", Nature Genet., 18:53-55, 1998
	31	Singh et al., "A Novel Potassium Channel Gene, <i>KCNQ2</i> , is Mutated in an Inherited Epilepsy of Newborns", Nature Genet., 18:25-29, 1998
	32	Biervert et al., "A Potassium Channel Mutation in Neonatal Human Epilepsy", Science, 279:403-406, 1998
	33	Burgess et al., "Mutation of the Ca ²⁺ Channel β Subunit Gene <i>Cchb4</i> is Associated with Ataxia and Seizures in the Lethargic (<i>lh</i>) Mouse", Cell, 88:385-392, 1997
	34	Fletcher et al., "Absence Epilepsy in Tottering Mutant Mice is Associated with Calcium Channel Defects", Cell, 87:607-617, 1996
	35	Wang et al., "Structural Requirement of the Calcium-channel subunit $\alpha 2\delta$ for Gabapentin Binding", Biochem. J., 342:313-320, 1999
	36	Stefani et al., "Gabapentin Inhibits Calcium Currents in Isolated Rat Brain Neurons", Neuropharmacology, 37:83-91, 1998
	37	Burgess & Noebels, "Single Gene Defects in Mice: The Role of Voltage-dependent Calcium Channels in Absence Model", Epilepsy Research, 36:111-122, 1999
	39	Needleman & Wunsch, "A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins", J. Mol. Biol., 48:443-453, 1970
	39	Smith & Waterman, "Comparison of Biosequences", Advances in Applied Mathematics, 2:482-489, 1981
	40	Rothenberg, M., et al., "Oligodeoxynucleotides as Anti-sense Inhibitors of Gene Expression: Therapeutic Implications", Journal of the National Cancer Institute, 81(20):1539-1544, 1989
	41	Nielsen, P. E., et al., "Peptide Nucleic Acids (PNAs): Potential Anti-sense and Anti-gene Agents", Anti-Cancer Drug Design, 8:53-63, 1993
	42	Mizushima & Nagata, "pEF-BOS, a Powerful Mammalian Expression Vector", Nucleic Acids Research, 18(17):5322, 1990
	43	Demoulin et al., "A Single Tyrosine of the Interleukin-9 (IL-9) eceptor is Required for STAT Activation, Antiapoptotic Activity, and Growth Regulation by IL-9", Molecular and Cellular Biology, 16(9):4710-4716, 1996
	44	Gregoriadis, G., "Liposomes for Drugs and Vaccines", Trends in Biotechnology, 3(9):235-241, 1985

Examiner Signature	Date Considered
--------------------	-----------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 8/24/2006

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			COMPLETE IF KNOWN		
			Application Number	10/553,117	
			Filing Date	October 13, 2005	
			First Named Inventor	Aiyar et al.	
			Group Art Unit		
			Examiner Name		
Sheet	5	of	8	Attorney Docket Number	MS0019P

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
	45	Hyrup, B. et al., "Peptide Nucleic Acids (PNA): Synthesis, Properties and Potential Applications", Bioorganic & Medicinal Chemistry, 4(1):5-23, 1996
	46	Perry-O'Keefe et al., "Peptide Nucleic Acid Pre-gel Hybridization: An Alternative to Southern Hybridization", Proc. Natl. Acad. Sci., 93:14670-675 (1996)
	47	Finn, P. J. et al., "Synthesis and Properties of DNA-PNA Chimeric Oligomers", Nucleic Acids Research, 24(17):3357-3363, 1996
	48	Mag, M. et al., "Synthesis and Selective Cleavage of Oligodeoxyribonucleotides Containing Non-chiral Internucleotide Phosphoramidate Linkages", Nucleic Acids Research, 17(15):5973-5988, 1989
	49	Petersen, K. H. et al., "A PNA-DNA Linker Synthesis of N-((4,4'-Dimethoxytrityloxy)Ethyl)-N-(Thymine-1-Ylacyl)Glycine", Bioorganic Medicinal Chemistry Letters, 5(11):1119-1124, 1995
	50	Letsinger et al., "Cholesteryl-conjugated Oligonucleotides: Synthesis, Properties, and Activity as Inhibitors of Replication of Human Immunodeficiency Virus in Cell Culture", Proc. Natl. Acad. Sci., 86:6553-6556, 1989
	51	Dahiyat & Mayo, "De Novo Protein Design: Fully Automated Sequence Selection", Science, 278:82-87, 1997
	52	Lin et al., "Identification of Functionally Distinct Isoforms of the N-Type Ca ²⁺ Channel in Rat Sympathetic Ganglia and Brain", Neuron, 18:153-166, 1997
	53	Henikoff & Henikoff, "Amino Acid Substitution Matrices from Protein Blocks", Proc. Natl. Acad. Sci., 89:10915-10919, 1992
	54	Kozber, J. et al., "A Human Hybrid Myeloma for Production of Human Monoclonal Antibodies", J. of Immunology., 133(6):3001-3005, 1984
	55	Brodeur et al., "Mouse-Human Myeloma Partners for the Production of Heterohybridomas", Monoclonal Antibody Production Techniques & Applications, Marcel Dekker Inc., New York, p. 51-63, 1987
	56	Jakobovits et al., "Analysis of Homozygous Mutant Chimeric Mice: Deletion of the Immunoglobulin Heavy-chain Joining Region Blocks B-cell Development and Antibody Production", Proc. Natl. Acad. Sci., 90:2551-2555, 1993
	57	Clark, W. R., The Experimental Foundations of Modern Immunology, Fourth Edition, John Wiley & Sons, New York, 1991
	58	Better et al., "Escherichia Coli Secretion of an Active Chimeric Antibody Fragment", Science, 240:1041-1043; 1988
	59	Liu et al., "Chimeric mouse-human IgG1 Antibody That Can Mediate Lysis of Cancer Cells", Proc. Natl. Acad. Sci., 84:3439-3443, 1987

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				COMPLETE IF KNOWN	
				Application Number	10/553,117
				Filing Date	October 13, 2005
				First Named Inventor	Aiyar et al.
				Group Art Unit	
Examiner Name					
Sheet	6	of	8	Attorney Docket Number	MS0019P

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
	60	Oi et al., "Chimeric Antibodies", Bio Techniques, 4(3):214-220, 1986
	61	Ward et al., "Binding Activities of a Repertoire of Single Immunoglobulin Variable Domains Secreted From <i>Escherichia Coli</i> ", Nature, 341:544-546, 1989
	62	Lazereno & Birdsall, "Pharmacological Characterization of Acetylcholine-stimulated [35S]-GTPγS Binding Mediated by Human Muscarinic m1-m4 Receptors: Antagonist Studies", Br. J. Pharmacol., 109:1120-1127, 1993
	63	Coward, P. et al., "Chimeric G Proteins Allow a High-Throughput Signaling Assay of Gi-Coupled Receptors", Analytical Biochemistry, 270:242-248, 1999
	64	Sebastian Lazareno, "Measurement of Agonist-Stimulated [35S]GTPγS Binding to Cell Membranes", Methods in Molecular Biology, 106:231-245 (1999)
	65	Zlokarnik et al., "Quantitation of Transcription and Clonal Selection of Single Living Cells with β-Lactamase as Reporter", Science, 279:84-88, 1998
	66	Wainscott et al., "Pharmacological Characteristics of the Newly Cloned Rat 5-Hydroxytryptamine 2F Receptor", Mol. Pharmacol., 43:419-426, 1992
	67	Fields, S. and Song, O., "A Novel Genetic System to Detect Protein-protein Interactions", Nature, 340:245-246, 1989
	68	Ho et al., "Dimeric Ligands Define a Role for Transcriptional Activation Domains in Reinitiation", Nature, 382:822-826, 1996
	69	Licitra & Liu, "A Three-hybrid Ssystem for Detecting Small Ligan-Protein Receptor Interactions", Proc. Natl. Acad. Sci., 93:12817-12821, 1996
	70	Young et al., "Identification of a Calcium Channel Modulator Using a High Throughput Yeast Two-hybrid Screen", Nature Biotech, 16:946-950, 1998
	71	Wahl et al., "Improved Radioimaging and Tumor Localization with Monoclonal F(ab') ₂ , Journal of Nuclear Medicine, 24(4):316-325, 1983
	72	Mishina et al., "Location of Functional Regions of Acetylcholine Receptor α-subunit by Site-directed Mutagenesis", Nature, 313:364-369; 1985
	73	Noda et al., "Expression of Functional Sodium Channels From Cloned cDNA", Nature, 322:826-828
	74	Price, C. M., "Fluorescence In Situ Hybridization", Blood Rev., 7:127-134, 1993

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 8/24/2006

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			COMPLETE IF KNOWN		
			Application Number	10/553,117	
			Filing Date	October 13, 2005	
			First Named Inventor	Aiyar et al.	
			Group Art Unit		
			Examiner Name		
Sheet	7	of	8	Attorney Docket Number	MS0019P

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
	75	Trask, B. J., "Fluorescence <i>in situ</i> Hybridization: Applications in Cytogenetics and Gene Mapping", Trends Genet., 7(5):149-154, 1991
	76	Egeland, J. et al., "Bipolar Affective Disorders Linked to DNA Markers on Chromosome 11", Nature, 325:783-787, 1987
	77	D'Eustachio P. et al., "Somatic Cell Genetics and Gene Families", Science, 220:919-924, 1983
	78	Verma et al., Human Chromosomes: A Manual of Basic Techniques, Pergamon Press, New York, 1989
	79	Fan, Y. et al., "Mapping Small DNA Sequences by Fluorescence <i>in situ</i> Hybridization Directly on Banded Metaphase Chromosomes", Proc. Natl. Acad. Sci., 87:6223-6227, 1990
	80	Gatti, R. A. et al., "Localization of an Ataxia-telangiectasia Gene to Chromosome 11q22-23", Nature, 336:577-580, 1988
	81	Lichtenstein, C., "Anti-sense RNA as a Tool to Study Plant Gene Expression", Nature, 333:801-802, 1988
	82	Cohen, Jack S., "Designing Antisense Oligonucleotides as Pharmaceutical Agents", Trends in Pharm. Sci., 10:435-437, 1989
	83	Weintraub, Harold M., "Antisense RNA and DNA", Scientific American, 262:40-46, 1990
	84	Sarver et al., "Ribozymes as Potential Anti-HIV-1 Therapeutic Agents", Science, 247:1222-1225, 1990
	85	Maddox, D. E. et al., "Elevated Serum Levels in Human Pregnancy of a Molecule Immunologically Similar to Eosinophil Granule Major Basic Protein", J. Exp. Med., 158:1211-1226, 1983
	86	Melby, P. C. et al., "Quantitative Measurement of Human Cytokine Gene Expression by Polymerase Chain Reaction", J. Immunological Methods, 159:235-244, 1993
	87	Duplaa, C. et al., "Quantitative Analysis of Polymerase Chain Reaction Products Using Biotinylated dUTP Incorporation", Analytical Biochemistry, 212:229-236 (1993)
	88	Brinster et al., "Factors Affecting the Efficiency of Introducing Foreign DNA Into Mice by Microinjecting Eggs", Proc. Natl. Acad. Sci., 82:4438-4442, 1985
	89	Brinster et al., "Somatic Expression of Herpes Thymidine Kinase in Mice Following Injection of a Fusion Gene into Eggs", Cell, 27:223-231, 1981

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 8/24/2006

[illegible]

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 8/24/2006